Our most advanced program, Neihulizumab, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
The company has also developed a proprietary linker-payload platform, which successfully overcomes major obstacles in the development of antibody-drug conjugate (ADC). Our biobetter/biosuperior ADCs have shown greater antitumor activity and safety profiles.
Our lead inflammation drug candidate, Neihulizumab (AbGn-168H) is an immune checkpoint agonist antibody targeting PSGL-1/CD162 that regulates T cell homeostasis. This compound triggers a natural regulatory mechanism of T cell homeostasis in late stage activated T cells without affecting normal immune defenses. It has demonstrated proof-of-concept clinical efficacy in psoriasis as well as psoriatic arthritis, both of which are established T cell mediated diseases, and is currently being studied for the treatment of ulcerative colitis (phase II) and steroid refractory-acute GvHD (phase I).
Neihulizumab's (AbGn-168H) unique mechanism of action provides a natural regulation of T cell homeostasis that induces cell death preferentially in late-stage activated T cells without affecting resting T cells and early-activated T cells. Because pathogenic T cells underlying the inflammatory conditions are usually in late-stage (chronically) activated state, eliminating this population of cells can potentially result in controlling autoimmune inflammation of T cell associated diseases, such as psoriasis, psoriatic arthritis, ulcerative colitis, multiple sclerosis, Type 1 diabetes and GvHD. Treatment with AbGn-168H could result in durable and long-term responses as the therapy is designed to eliminate the pathogenic T cells underlying these inflammatory conditions rather than simply inhibit them. In addition, since resting T cells are not affected, normal immune defenses are not impacted.
Neihulizumab (AbGn-168H) has demonstrated signs of clinical efficacy in Psoriasis and Psoriatic Arthritis, both of which are T-cell mediated diseases, and is being studied for the treatment of Ulcerative Colitis (phase II, NCT03298022) and steroid refractory-acute GvHD (phase I, NCT03327857).
Antibody-drug conjugate (ADC) delivers a potent "missile" to targeted tumor cells and is currently the most efficacious agent known for cancer therapy. Many ADCs have been clinically tested but a large portion of them failed due to toxic side effects caused by on-target toxicity, which is determined by the targeting antibody. The targeting antibodies used in our biosuperior ADCs have all been clinically validated for their safety. This early stringent selection of targeting antibodies significantly eliminates the risk of toxicity in the downstream development of our biobetter/biosuperior ADC candidates. As a result, our best-in-class ADCs have potential to achieve a successful clinical outcome.
Our lead ADC candidate, AbGn-107, is currently being tested in treating chemo-refractory gastric, pancreatic, colorectal and biliary cancers (NCT02908451).
We are committed to responsible intellectual property management, creating a strong foundation for innovation.
In an effort to protect and expand our intellectual property portfolio, AbGenomics actively pursues domestic and international patents for any commercially valuable inventions.